Diagnosis and therapy of esophageal vascular disorders

Current Opinion in Gastroenterology

Volumn 23, Issue 4, 2007, Pages 422-427

  De Franchis, Roberto ^a,b   Dell'Era, Alessandra ^a,b  

^a UNIVERSITY OF MILAN   (Italy)

^b FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

Beta blockers; Endoscopic band ligation; Esophageal varices; Variceal bleeding

Indexed keywords

ANTIBIOTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOCHEMICAL MARKER; CANRENOATE POTASSIUM; ISOSORBIDE 5 NITRATE; NADOLOL; PLACEBO; PROPRANOLOL; SOMATOSTATIN; VASOACTIVE AGENT;

ANTIBIOTIC PROPHYLAXIS; BLOOD PRESSURE MONITORING; CAPSULE ENDOSCOPE; CAPSULE ENDOSCOPY; CLINICAL TRIAL; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; DISEASE COURSE; DISTAL SPLENORENAL SHUNT; DRUG DOSE COMPARISON; ECHOGRAPHY; ENDOSCOPIC SCLEROTHERAPY; ENDOSCOPIC SURGERY; ESOPHAGOGASTRODUODENOSCOPY; ESOPHAGOSCOPY; ESOPHAGUS VARICES; ESOPHAGUS VARICES BLEEDING; H GRAFT; HEMODYNAMICS; HEPATIC VEIN; HUMAN; INTERMETHOD COMPARISON; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER FUNCTION TEST; MORTALITY; NON INVASIVE MEASUREMENT; PORTOSYSTEMIC ANASTOMOSIS; PRESSURE GRADIENT; PRIMARY PREVENTION; PROGNOSIS; RECURRENT DISEASE; REVIEW; SECONDARY PREVENTION; SPLEEN; STENT; SURGICAL TECHNIQUE; THROMBOCYTE COUNT; TRANSIENT ELASTOGRAPHY; TREATMENT OUTCOME; VEIN LIGATION; VENOUS PRESSURE;

ADRENERGIC BETA-ANTAGONISTS; BIOLOGICAL MARKERS; CAPSULE ENDOSCOPY; ESOPHAGEAL AND GASTRIC VARICES; ESOPHAGOSCOPY; GASTROINTESTINAL HEMORRHAGE; HUMANS; LIGATION; PLATELET COUNT; PORTASYSTEMIC SHUNT, TRANSJUGULAR INTRAHEPATIC; SPLEEN; STENTS; VASOCONSTRICTOR AGENTS;

EID: 34249937390     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOG.0b013e3281299011     Document Type: Review

References (60)

1. de Franchis R. Updating consensus in portal hypertension: Report of the Baveno III consensus workshop on definitions, methodology and therapeutic strategies in portal hypertension. J Hepatol 2000; 33:846-852.
2. de Franchis R. Evolving Consensus in Portal Hypertension Report of the Baveno IV Consensus Workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol 2005; 43:167-176.
3. Pascal J, Calés P, Desmorat H. Natural history of esophageal varices. In: Bosch J, Rodes J, editors. Recent advances in the pathophysiology and treatment of portal hypertension. Serono Symposia review no. 22. Rome; 1989. pp. 127-142.
4. Ng F, Wong S, Loo C, et al. Prediction of oesophagogastric varices in patients with liver cirrhosis. J Gastroenterol Hepatol 1999; 14:785-790.
5. Pilette C, Oberti F, Aube C, et al. Noninvasive diagnosis of esophageal varices in chronic liver diseases. J Hepatol 1999; 31:867-873.
6. Chalasani N, Imperiale T, Ismail A. Predictors of large esophageal varices in cirrhosis. Am J Gastroenterol 1999; 94:3103-3105.
7. Schepis F, Cammà C, Niceforo D, et al. Which patients should undergo endoscopic screening for esophageal varices detection? Hepatology 2001; 33:333-338.
8. Zaman A, Becker T, Lapidus J, et al. Risk factors for the presence of varices in cirrhotic patients without history of variceal hemorrhage. Arch Intern Med 2001; 161:2564-2570.
9. Madhotra R, Mulcahy H, Willner I, et al. Prediction of esophageal varices in patients with cirrhosis. J Clin Gastroenterol 2002; 34:81-85.
10. Thomopoulos K, Labropoulou-Karatza C, Mimidis K, et al. Noninvasive predictors of the presence of large oesophageal varices in patients with cirrhosis. Dig Dis Sci 2003; 35:473-478.
11. Zein C, Lindor K, Angulo P. Prevalence and predictors of esophageal varices in patients with primary sclerosing cholangitis. Hepatology 2004; 39:204-210.
12. Pagliaro L, D'Amico G, Pasta L, et al. Portal hypertension in cirrhosis: natural history. In: Bosch J, Groszmann R, editors. Portal hypertension, pathophysiology and treatment. Oxford: Blackwell; 1994. pp. 72-92.
13. Cottone M, D'Amico G, Maringhini A, et al. Predictive value of ultrasonography in the screening of nonascitic cirrhotic patients with large varices. J Ultrasound Med 1986; 5:189-192.
14. Sanyal A, Fontana R, Everhart J, et al. The prevalence and risk factors associated with esophageal varices in subjects with hepatitis C and advanced fibrosis. Gastrointest Endosc 2006; 64:855-864. Identification of risk factors for the presence of esophageal varices in subjects with hepatitis C.
15. Charuworn P, Cheung R. Screening for esophageal varices in cirrhotic patients: endoscope, platelet count, or both? Gastrointest Endosc 2006; 64:865-867. Editorial commenting on risk factors for presence of varices in cirrhotic patients.
16. Giannini E, Botta F, Borro P. Platelet count/spleen diameter ratio: Proposal and validation of a noninvasive parameter to predict the presence of oesophageal varices in patients with liver cirrhosis. Gut 2003; 52:1200-1205.
17. Giannini E, Zaman A, Kreil A, et al. Platelet count/spleen diameter ratio for the noninvasive diagnosis of esophageal varices: results of a multicenter, prospective, validation study. Am J Gastroenterol 2006; 101:2511-2519. Trial of validation of the platelet count/spleen diameter as a predictive index of presence of esophageal varices in cirrhotic patients.
18. de Franchis R. Noninvasive diagnosis of sophageal varices: is it feasible? Am J Gastroenterol 2006; 101:2520-2522. Editorial that comments on invasive methods of diagnosis of esophageal varices and the trial of validation of platelet count/spleen diameter ratio index.
19. Sandrin L, Fourquet B, Hasquenoph J, et al. Transient elastography: A new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol 2003; 29:1705-1713.
20. Kazemi F, Kettaneh A, N'kontchou G, et al. Liver stiffness measurement selects patients with cirrhosis at risk of bearing large oesophageal varices. J Hepatol 2006; 45:230-235. Fibroscan may be used as a non-invasive method to identify patients at risk of having large esophageal varices.
21. Thabut D, Imbert-Bismuth F, Cazals-Hatem D, et al. Diagnostic value of fibrosis biochemical markers (Fibrotest-Fibrosure) for the prediction of severe portal hypertension in patients with and without cirrhosis. Hepatology 2004; 40:202A-203A.
22. Thabut D, Trabut J, Massard J, et al. Noninvasive diagnosis of large oesophageal varices with Fibro Test in patients with cirrhosis: a preliminary retrospective study. Liver Int 2006; 26:271-278. Interesting paper on the use of biochemical marker as non-invasive method to identify patients at risk of having large esophageal varices.
23. Bosch J. Predictions from a hard liver. J Hepatol 2006; 45:174-177. Discusses the usefulness of liver stiffness for the identification of the presence of varices.
24. Eisen G, Eliakim R, Zaman A, et al. The accuracy of PillCam ESO capsule endoscopy versus conventional upper endoscopy for the diagnosis of esophageal varices: a prospective three-center pilot study. Endoscopy 2006; 38:31-35. Pilot study showing that the PillCam ESO might be an alternative to EGDS for screening or surveillance of esophageal varices in cirrhotic patients.
25. Lapalus M, Dumortier J, Fumex F, et al. Esophageal capsule endoscopy versus esophagogastroduodenoscopy for evaluating portal hypertension: a prospective comparative study of performance and tolerance. Endoscopy 2006; 38:36-41. Pilot study showing that the PillCam ESO might be an alternative to EGDS for screening or surveillance of esophageal varices in cirrhotic patients.
26. Sanchez-Yague A, Caunedo-Alvarez A, Garcia-Montes J, et al. Esophageal capsule endoscopy in patients refusing conventional endoscopy for the study of suspected esophageal pathology. Eur J Gastroenterol Hepatol 2006; 18:977-983.
27. Bolondi L, Piscaglia F, Gatta A, et al. Effect of potassium canrenoate, an antialdosterone agent, on incidence of ascites and variceal progression in cirrhosis. Clin Gastroenterol Hepatol 2006; 4:1395-1402. Trial on potassium canrenoate showing no effect on the development/progression of esophageal varices.
28. Khuroo MS, Khuroo NS, Farahat KLC, et al. Meta-analysis: endoscopic variceal ligation for primary prophylaxis of oesophageal variceal bleeding. Aliment Pharmacol Ther 2005; 21:347-361.
29. Lay C, Tsai Y, Lee F, et al. Endoscopic variceal ligation versus propranolol in prophylaxis of first variceal bleeding in patients with cirrhosis. J Gastroenterol Hepatol 2006; 21:413-419. In primary prophylaxis beta blockers and EBL have similar effects on bleeding and mortality.
30. Gheorghe C, Gheorghe L, Iacob S, et al. Primary prophylaxis of variceal bleeding in cirrhotics awaiting liver transplantation. Hepatogastroenterology 2006; 53:552-557. The association of band ligation with beta blockers in primary prophylaxis of patients awaiting liver transplantation reduces the incidence of bleeding.
31. Turnes J, Garcia-Pagan J, Abraldes J, et al. Pharmacological reduction of portal pressure and long-term risk of first variceal bleeding in patients with cirrhosis. Am J Gastroenterol 2006; 101:506-512. Demonstration that haemodynamic response to beta blockers has a long term protective effect from variceal bleeding.
32. Berzigotti A, Rinaldi M, Magalotti D, et al. Primary prophylaxis with nadolol in cirrhotic patients: Doppler patterns of splanchnic hemodynamics in good and poor responders. J Hepatol 2006; 44:310-316. Echo-colour-Doppler patterns may not be used as a non-invasive substitute of HVPG measurement.
33. de Franchis R. Developing consensus in portal hypertension. J Hepatol 1996; 25:390-394.
34. Ingrand P, Gournay J, Bernard P, et al. Management of digestive bleeding related to portal hypertension in cirrhotic patients: A French multicenter crosssectional practice survey. World J Gastroenterol 2006; 12:7810-7814. In France there is only partial adherence to current guidelines on treatment of portal hypertensive bleeding.
35. Cheung J, Wong W, Zandieh I, et al. Acute management and secondary prophylaxis of esophageal variceal bleeding: a western Canadian survey. Can J Gastroenterol 2006; 20:531-534. The application of guidelines on management and secondary prophylaxis of variceal bleeding in Canada is far from satisfactory.
36. Palazon J, Such J, Sanchez-Paya J, et al. A comparison of two different dosages of somatostatin combined with sclerotherapy for the treatment of acute esophageal variceal bleeding: a prospective randomized trial. Rev Esp Enferm Dig 2006; 98:249-254. Higher doses of somatostatin in association with sclerotherapy are associated with lower rates of early rebleeding.
37. Moitinho E, Planas R, Banares R, et al. Multicenter randomized controlled trial comparing different schedules of somatostatin in the treatment of acute variceal bleeding. J Hepatol 2001; 35:712-718.
38. Villanueva C, Piqueras M, Aracil C, et al. A randomized controlled trial comparing ligation and sclerotherapy as emergency endoscopic treatment added to somatostatin in acute variceal bleeding. J Hepatol 2006; 45:560-567. EBL is better than EVS as endoscopic treatment for variceal bleeding in conjunction with vasoactive drug treatment.
39. Hubmann R, Bodlaj G, Czompo M, et al. The use of self-expanding metal stents to treat acute esophageal variceal bleeding. Endoscopy 2006; 38:896-901. Interesting pilot study showing that self-expanding metal stents are effective as bridge therapy for massive esophageal bleeding.
40. D'Amico G, de Franchis R. Upper digestive bleeding in cirrhosis. Posttherapeutic outcome and prognostic indicators. Hepatology 2003; 38:599-612.
41. McAvoy N, Hayes P. The use of transjugular intrahepatic portosystemic stent shunt in the management of acute oesophageal variceal haemorrhage. Eur J Gastroenterol Hepatol 2006; 18:1135-1141. Comprehensive review on the use of TIPS in the treatment of acute esophageal bleeding.
42. de Franchis R, Pascal JP, Ancona E, et al. Definitions, methodology and therapeutic strategies in portal hypertension. J Hepatol 1992; 15:256-261.
43. Romero G, Kravetz D, Argonz J, et al. Comparative study between nadolol and 5-isosorbide mononitrate vs. endoscopic band ligation plus sclerotherapy in the prevention of variceal rebleeding in cirrhotic patients: a randomized controlled trial. Aliment Pharmacol Ther 2006; 24:601-611. EBL and nadolol are equally effective in preventing rebleeding from esophageal varices.
44. Ferguson J, Hayes P. Transjugular intrahepatic portosystemic shunt in the prevention of rebleeding in oesophageal varices. Eur J Gastroenterol Hepatol 2006; 18:1167-1171. TIPS cannot be proposed as a first-line alternative to beta-blockers or band ligation for prevention of rebleeding.
45. Khan S, Tudur Smith C, Williamson P, Sutton R. Portosystemic shunts versus endoscopic therapy for variceal rebleeding in patients with cirrhosis. Cochrane Database Syst Rev 2006; (4):CD000553 Extensive review on portosystemic shunts and endoscopic therapy for variceal rebleeding.
46. Henderson J, Boyer T, Kutner M, et al. Distal splenorenal shunt versus transjugular intrahepatic portal systemic shunt for variceal bleeding: a randomized trial. Gastroenterology 2006; 130:1643-1651. Distal splenorenal shunt and TIPS are equally effective in preventing rebleeding but TIPS is associated with higher reintervention rates.
47. Garden OJ, Motyl H, Gilmour WH, et al. Prediction of outcome following acute variceal haemorrhage. Br J Surg 1985; 72:91-95.
48. Gatta A, Merkel C, Amodio P, et al. Development and validation of a prognostic index predicting death after upper gastrointestinal bleeding in patients with liver cirrhosis: a multicenter study. Am J Gastroenterol 1994; 89:1528-1536.
49. Graham D, Smith J. The course of patients after variceal hemorrhage. Gastroenterology 1981; 80:800-806.
50. Bernard B, Cadranel JF, Valla D, et al. Prognostic significance of bacterial infection in bleeding cirrhotic patients: a prospective study. Gastroenterology 1995; 108:1828-1834.
51. Cardenas A, Gines P, Uriz J, et al. Renal failure after upper gastrointestinal bleeding in cirrhosis: incidence, clinical course, predictive factors, and shortterm prognosis. Hepatology 2001; 34:671-676.
52. Goulis J, Armonis A, Patch D, et al. Bacterial infection is independently associated with failure to control bleeding in cirrhotic patients with gastrointestinal hemorrhage. Hepatology 1998; 27:1207-1212.
53. Vivas S, Rodriguez M, Palacio MA, et al. Presence of bacterial infection in bleeding cirrhotic patients is independently associated with early mortality and failure to control bleeding. Dig Dis Sci 2001; 46:2752-2757.
54. Ben Ari Z, Cardin F, McCormick AP, et al. A predictive model for failure to control bleeding during acute variceal haemorrhage. J Hepatol 1999; 31:443-450.
55. Garcia-Pagan JC, Escorsell A, Moitinho E, Bosch J. Influence of pharmacological agents on portal hemodynamics: Basis for its use in the treatment of portal hypertension. Semin Liver Dis 1999; 19:427-438.
56. Moitinho E, Escorsell A, Bandi JC, et al. Prognostic value of early measurements of portal pressure in acute variceal bleeding. Gastroenterology 1999; 117:626-631.
57. Monescillo A, Martinez-Lagares F, Ruiz-del-Arbol L, et al. Influence of portal hypertension and its early decompression by TIPS placement on the outcome of variceal bleeding. Hepatology 2004; 40:793-801.
58. Thomopoulos K, Theocharis G, Mimidis K, et al. Improved survival of patients presenting with acute variceal bleeding. Prognostic indicators of short-and long-term mortality. Dig Dis Sci 2006; 38:899-904. Identification of risk factors for early and 1-year mortality in patients with variceal bleeding.
59. Hori S, Takaki A, Okada H, et al. Endoscopic therapy for bleeding esophageal varices improves the outcome of Child C cirrhotic patients. J Gastroenterol Hepatol 2006; 21:1704-1709. Endoscopic therapy is effective in controlling variceal haemorrhage in cirrhotic patients. The prognosis depends on the degree of liver failure and the presence of hepatocellular carcinoma.
60. Stokkeland K, Brandt L, Ekbom A, Hultcrantz R. Improved prognosis for patients hospitalized with esophageal varices in Sweden 1969-2002. Hepatology 2006; 43:500-505. Nice population-based study showing how prognosis for patients with variceal bleeding has steadily improved in the last decades.